Holen Sie sich die Stockscreener-App
7.925
16.22%
-1.445
Schlusskurs vom Vortag:
$9.37
Offen:
$9.44
24-Stunden-Volumen:
33,777
Relative Volume:
0.39
Marktkapitalisierung:
$13.07M
Einnahmen:
$368.00K
Nettoeinkommen (Verlust:
$-9.54M
KGV:
-16.55
EPS:
-0.4788
Netto-Cashflow:
$-9.47M
1W Leistung:
-40.55%
1M Leistung:
+48.96%
6M Leistung:
+976.08%
1J Leistung:
+685.16%
1-Tages-Spanne:
$7.893
$9.52
1-Wochen-Bereich:
$7.893
$14.37
52-Wochen-Spanne:
$0.35
$14.37
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Firmenname
Lexaria Bioscience Corp
Sektor
Branche
Telefon
250-765-6424
Adresse
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
7.91 | 15.48M | 368.00K | -9.54M | -9.47M | -0.4788 |
VRTX
Vertex Pharmaceuticals Inc
|
520.95 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.06 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,005.68 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.24 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.87 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lexaria Bioscience Corp Aktie (LEXX) Neueste Nachrichten
Lexaria Bioscience Raises $5.9 Million Via Warrant Exercise; Issues New Warrants, Engages Wainwright - TradingView
Lexaria Raises $5.9 Million Via Warrant Exercise and Issues New Warrants - TipRanks
Lexaria raises $5.9M by exercising warrants at reduced price to fund 2027 operations and R&D. - Pluang
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds - Investing News Network
Lexaria Announces Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds - TradingView
A potential $5.9 million plus a $2.6 million rebate may fund Lexaria's 2027 research - Stock Titan
LEXX: Introducing DehydraTECH 3.0 - finance.yahoo.com
Lexaria Bioscience Corp (NASDAQ: LEXX) Share Price, LEXX Stock News, LEXX Share Price & Updates - Kalkine
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Investing News Network
Lexaria to present at H.C. Wainwright Global Investment Conference in September 2026 - Pluang
A drug-delivery company holds 66 granted patents. Lexaria plans a New York presentation. - Stock Titan
Lexaria Bioscience Corp. (LEXX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Lexaria Bioscience: Advancing Next-Generation Oral Weight-Loss Drugs - The Globe and Mail
LEXX Looks 131.9% Overvalued on GF Value™ - GuruFocus
Lexaria Bioscience advances 12% on Australian tax rebate (LEXX:NASDAQ) - Seeking Alpha
Lexaria enters MTA with PegBio to test GLP-1 delivery tech - scanx.trade
LEXX Looks 129.0% Overvalued on GF Value™ - GuruFocus
Lexaria advances GLP-1 partnerships at BIO 2026 - scanx.trade
Lexaria Bioscience Receives Australian R&D Tax Incentive Credit - TipRanks
LEXX Looks 117.5% Overvalued on GF Value™ - GuruFocus
Lexaria receives $2.6 million Australian R&D tax rebate By Investing.com - Investing.com South Africa
Lexaria Bioscience receives AUD$3.67m Australian tax rebate - scanx.trade
Lexaria receives $2.6 million Australian R&D tax rebate - Investing.com
Lexaria nets $2.6M Australian tax rebate to fun... - Pluang
Lexaria Bioscience receives AUD 3.67M Australian R&D tax credit to fund clinical RD - TradingView
Lexaria Receives USD$2.6 Million Tax Rebate Payment - New Castle News
Lexaria DehydraTECH 3.0 Boosts GLP-1 Drug Absorption in 2026 Study - TipRanks
DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2 - finance.yahoo.com
Lexaria Bioscience regains Nasdaq compliance, stock to remain listed By Investing.com - Investing.com India
Form 8K LEXARIA BIOSCIENCE CORP. For: 17 August By Investing.com - Investing.com Nigeria
Lexaria Bioscience Regains Nasdaq Compliance, Stabilizing Listing - TipRanks
Lexaria Bioscience regains Nasdaq compliance, stock to remain listed - Investing.com
Lexaria Bioscience regains Nasdaq bid-price compliance, listing continued - TradingView
Delisting risk eases as Lexaria (NASDAQ: LEXX) regains bid-price compliance - Stock Titan
Lexaria Bioscience enters MTA with PegBio - TipRanks
LEXX Looks 64.3% Overvalued on GF Value™ - GuruFocus
Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know - Benzinga
Lexaria Signs PegBio Deal to Test DehydraTECH With GLP-1 Diabetes Drug - TipRanks
Lexaria Bioscience Corp. Enters Material Transfer Agreement with Pegbio Co., Ltd - marketscreener.com
Lexaria enters partnership with PegBio for GLP-1 drug delivery By Investing.com - Investing.com Australia
Lexaria enters partnership with PegBio for GLP-1 drug delivery - Investing.com
Lexaria Enters a Material Transfer Agreement With PegBio - Investing News Network
Lexaria Enters a Material Transfer Agreement with PegBio - TradingView
Lexaria and PegBio Plan Animal Studies on a GLP-1 Molecule - Stock Titan
Lexaria Bioscience Received Notice of Delisting - TradingView
Lexaria Bioscience Corp (LEXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lexaria Bioscience Stock Price Forecast. Should You Buy LEXX? - StockInvest.us
Lexaria Bioscience Corp (LEXX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lexaria Bioscience Corp (LEXX) Stock News Today - TradingKey
Lexaria Provides Update on Human Nicotine Study NIC-H22-1 - TheNewswire
Lexaria Bioscience Corp Authorizes 1-For-15 Reverse Stock SplitSEC Filing - TradingView
Finanzdaten der Lexaria Bioscience Corp-Aktie (LEXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
2.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):